DUBLIN, IE and VANCOUVER, BC — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (NYSE: ZYME) today announced that Jazz and Zymeworks’ subsidiary, Zymeworks BC Inc., have entered into an exclusive licensing agreement… Read More
Surgical site infections reduced by an average of 47% across all surgery types (P=0.01). Most significant impact seen in cardiac surgeries – almost 70% reduction (P=0.02). Mortality rate cut by… Read More
Evusheld is the first long-acting antibody (LAAB) combination to receive Health Canada authorization for both the prevention and treatment of COVID-19 Evusheld significantly reduced risk of severe COVID-19 or death in… Read More
Quebec leads the way as the first province to reimburse Luxturna® (voretigene neparvovec) for previously untreatable inherited retinal disease1 Approved by Health Canada in 2020, Luxturna® is a one-time gene therapy that… Read More
TORONTO, ON, October 17, 2022 – adMare BioInnovations (adMare) and Medicine by Design are pleased to announce their new memorandum of understanding (MOU) to support translation priorities, which will accelerate health innovation… Read More
